Clinical Trials
85
44 active
Approvals
13
Total approvals
Agencies
4
Regulatory bodies
Founded
N/A
Active, not recruiting
43
50.6%
Completed
28
32.9%
Not yet recruiting
1
1.2%
Recruiting
9
10.6%
Suspended
1
1.2%
Unknown
1
1.2%
Withdrawn
2
2.4%
- The EMA's CHMP recommended 12 new medicines for approval at its September 14-17, 2026 meeting, alongside 11 therapeutic indication extensions and two biosimilars. - Povofortay (povorcitinib) became the first oral daily treatment recommended for adults with moderate to severe hidradenitis suppurativa refractory or intolerant to anti-TNF therapy. - Johnson & Johnson's Tecvayli (teclistamab) won support for earlier-line multiple myeloma use, with MajesTEC-3 data showing a 71% reduction in progression risk versus standard of care. - Two initial marketing applications were withdrawn, for apitegromab in 5q spinal muscular atrophy and trilaciclib in extensive-stage small-cell lung cancer, while three negative opinions entered re-examination.
- China Medical System Holdings Limited has entered into an exclusive 15-year commercialization agreement with Pharmacosmos A/S for two intravenous iron products, Monofer® and Cosmofer®, in mainland China. - Monofer® represents the first third-generation intravenous iron therapy approved in China, featuring innovative nanostructure technology that enables single-dose full iron replenishment of 1,000 mg or more. - The partnership addresses significant unmet medical needs in China, where iron deficiency anemia affects 20.1% of residents but remains underdiagnosed and undertreated. - Both products are included in China's National Reimbursement Drug List, with Cosmofer® holding Category A status and inclusion in the National Essential Medicines List.
